| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| Other Sizes |
|
Purity: ≥98%
Corticosterone is an adrenocortical steroid and also an endogenous steroid hormone involved in immune responses, stress responses and energy homeostasis. It activates mineralocorticoid and glucocorticoid receptors.
| Targets |
Endogenoous glucocorticoid
|
|---|---|
| ln Vitro |
Corticosterone (100 nM; 30 minutes) phosphorylates GDI Ser-213 via SGK, enhances the GDI-Rab4 complex's formation, and encourages Rab4's functional recycling as well as Rab4-mediated AMPAR recycling to the synaptic membrane [1]. Good immunosuppressive characteristics are shown by corticosterone (CORT) (1 µM; 48 hours), which functionally inhibits BMDC maturation and hence inhibits LPS-induced maturation-related markers (MHC class II, B7.2, B7.1, and CD40) [2].
|
| ln Vivo |
Corticosterone significantly impairs BMDC cells' capacity to stimulate naive CD8+ T cells in vivo [2]. In the dentate gyrus and CA1 of rats, corticosterone (0.03 or 1 mg/kg; subcutaneous; single dosage) suppresses the expression of BDNF mRNA [3]. In adrenalectomized (ADX) rats, corticosterone (2.6 mg/kg; in animal feed; 8 days) returns ethanol intake and preference to about preoperative levels [4].
|
| Enzyme Assay |
Dendritic cells (DC) play a critical role in initiating and directing adaptive immune responses against pathogens and tumours. Immature DC are thought to act as sentinels in peripheral tissues where their main function is to capture antigen at sites of infection, whereas mature DC are highly efficient at priming T-cell-mediated immune responses against infectious pathogens. The DC maturation process is thought to be an important step in the efficient generation of cytotoxic T lymphocytes (CTL). It is well established that many aspects of immune function, including CTL-mediated antiviral immunity, are modulated by neuroendocrine-derived products. Corticosterone (CORT), an adrenal hormone produced at increased concentrations during a stress response, has been shown to play a role in impaired CTL responses in stressed animals, leading to high mortality in mice normally resistant to viral infection. While direct effects of neuroendocrine mediators on CTL have been studied, little is known about their effects on DC that are critical for CTL priming. Here, we found that physiologically relevant concentrations of CORT, acting via the glucocorticoid receptor, functionally compromise DC maturation. DC exposed to CORT remained phenotypically and functionally immature after stimulation with lipopolysaccharide and were impaired for the production of interleukin (IL)-6, IL-12, and tumour necrosis factor-alpha. These effects were biologically significant, as CORT treatment resulted in a marked reduction in the ability of DC to prime naive CD8(+) T cells in vivo. These findings offer a potential mechanism underlying stress-associated immunosuppression[1].
|
| Cell Assay |
Cell viability assay [2]
Cell Types: BMDC Cell Tested Concentrations: 1 µM Incubation Duration: 48 h Experimental Results: Completely blocked LPS-induced expression of MHC class II and B7.2, and maximally damaged BMDC cells at 12 h Mature. B7.1 diminished by 50%, and CD40 was slightly downregulated. |
| Animal Protocol |
Animal/Disease Models: Adult male Wistar rat (150-170 g; adrenalectomy) [3].
Doses: 0.03 or 1 mg/kg Route of Administration: subcutaneous injection; single. Experimental Results: The expression of BDNF mRNA in the dentate gyrus diminished by 25% and 50% at doses of 0.03 and 1 mg/kg (3 hrs (hrs (hours)) after administration). Compared with the control group at t=0 hrs (hrs (hours)) (3 hrs (hrs (hours)) after administration), BDNF mRNA levels diminished by approximately 40%, but levels increased by 100% at 12 hrs (hrs (hours)) after administration (compared with the t=3 hrs (hrs (hours)) and t=6 hrs (hrs (hours)) groups ). Animal/Disease Models: Male Wistar rat (3 weeks old; adrenalectomy) [4]. Doses: 2.6 mg/kg Route of Administration: Animal feed; 8 days. Experimental Results: Ethanol intake and preference in adrenalectomized (ADX) rats returned to approximately normal preoperative levels and to levels observed in sham-operated (SH) rats. |
| References |
|
| Additional Infomation |
Corticosterone is a 21-hydroxy steroid that consists of pregn-4-ene substituted by hydroxy groups at positions 11 and 21 and oxo groups at positions 3 and 20. Corticosterone is a 21-carbon steroid hormone of the corticosteroid type produced in the cortex of the adrenal glands. It has a role as a human metabolite and a mouse metabolite. It is an 11beta-hydroxy steroid, a 21-hydroxy steroid, a 20-oxo steroid, a C21-steroid, a 3-oxo-Delta(4) steroid, a primary alpha-hydroxy ketone and a glucocorticoid. It derives from a hydride of a pregnane.
An adrenocortical steroid that has modest but significant activities as a mineralocorticoid and a glucocorticoid. (From Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p1437) Corticosterone has been reported in Homo sapiens with data available. Corticosterone is a corticosteroid intermediate in the steroidogenic pathway that converts pregnenolone to aldosterone. In humans, corticosterone has limited glucocorticoid or mineralocorticoid activity. An adrenocortical steroid that has modest but significant activities as a mineralocorticoid and a glucocorticoid. (From Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p1437) |
| Molecular Formula |
C21H30O4
|
|---|---|
| Molecular Weight |
346.4605
|
| Exact Mass |
346.214
|
| Elemental Analysis |
C, 72.80; H, 8.73; O, 18.47
|
| CAS # |
50-22-6
|
| Related CAS # |
Corticosterone-d8;1271728-07-4;Corticosterone-d4;2243253-91-8
|
| PubChem CID |
5753
|
| Appearance |
White to off-white solid powder
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
529.2±50.0 °C at 760 mmHg
|
| Melting Point |
179-183 °C(lit.)
|
| Flash Point |
288.0±26.6 °C
|
| Vapour Pressure |
0.0±3.2 mmHg at 25°C
|
| Index of Refraction |
1.576
|
| LogP |
1.76
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
4
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
25
|
| Complexity |
638
|
| Defined Atom Stereocenter Count |
7
|
| SMILES |
O([H])[C@@]1([H])C([H])([H])[C@]2(C([H])([H])[H])[C@@]([H])(C(C([H])([H])O[H])=O)C([H])([H])C([H])([H])[C@@]2([H])[C@]2([H])C([H])([H])C([H])([H])C3=C([H])C(C([H])([H])C([H])([H])[C@]3(C([H])([H])[H])[C@]21[H])=O
|
| InChi Key |
OMFXVFTZEKFJBZ-HJTSIMOOSA-N
|
| InChi Code |
InChI=1S/C21H30O4/c1-20-8-7-13(23)9-12(20)3-4-14-15-5-6-16(18(25)11-22)21(15,2)10-17(24)19(14)20/h9,14-17,19,22,24H,3-8,10-11H2,1-2H3/t14-,15-,16+,17-,19+,20-,21-/m0/s1
|
| Chemical Name |
(8S,9S,10R,11S,13S,14S,17S)-11-hydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-3H-cyclopenta[a]phenanthren-3-one
|
| Synonyms |
BRN 2339601; BRN-233960; BRN233960 CCRIS 6753 CCRIS-6753 CCRIS6753 NSC 9705 NSC-9705 NSC9705
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~288.63 mM)
Ethanol : ~14.29 mg/mL (~41.25 mM) H2O : ~0.67 mg/mL (~1.93 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.22 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.22 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (7.22 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: ≥ 1.43 mg/mL (4.13 mM) (saturation unknown) in 10% EtOH + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 14.3 mg/mL clear EtOH stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 5: ≥ 1.43 mg/mL (4.13 mM) (saturation unknown) in 10% EtOH + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 14.3 mg/mL clear EtOH stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 6: ≥ 1.43 mg/mL (4.13 mM) (saturation unknown) in 10% EtOH + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 14.3 mg/mL clear EtOH stock solution to 900 μL of corn oil and mix well. Solubility in Formulation 7: 2 mg/mL (5.77 mM) in 0.5% CMC-Na/saline water (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication (<60°C). Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 8: 4 mg/mL (11.55 mM) in 20% HP-β-CD in Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 9: 5 mg/mL (14.43 mM) in 5% Cremophor EL 95% (20% HP-β-CD) (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.8863 mL | 14.4317 mL | 28.8634 mL | |
| 5 mM | 0.5773 mL | 2.8863 mL | 5.7727 mL | |
| 10 mM | 0.2886 mL | 1.4432 mL | 2.8863 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA